RICARDO
As part of its mission to support the decarbonisation of the global energy sector, Ricardo, a world-class, strategic environmental and engineering consulting company, has received 3million GBP from the UK Government to design, install and operate a combined heat and power demonstrator plant with a carbon negative footprint which will showcase climate repairing technology. The plant will demonstrate the effectiveness of community scale greenhouse gas removal and clean energy using sustainably-sourced forestry waste. The funding is awarded through the Net Zero Innovation Portfolio (NZIP) under the Department of Business, Energy and Industrial Strategy (BEIS).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220711005348/en/
Ricardo is leading the consortium delivering the demonstrator plant. The consortium combines an innovative carbon capture system developed by Ricardo with the hot air turbine technology from Bluebox Energy and pyrolysis technology from Woodtek Engineering. The quarter-sized demonstrator plant, which will be located at Holmsted Farm in West Sussex in the UK, will be commissioned and operational in 2023. It will demonstrate not only a highly innovative greenhouse gas removal technology, that in the full-size system can generate renewable heat and electricity for up to 300 local homes and businesses, but also a realistic carbon negative technology that can significantly contribute to net zero targets.
Tim Curtis, Managing Director, Ricardo Energy and Environment said: “Ricardo is a trusted advisor to governments around the world on climate change policy and the transition to clean energy, and is also well known for its mission to decarbonise the global transport and energy sectors. In partnership with Bluebox Energy and Woodtek Engineering, this project will demonstrate that our innovative and integrated carbon capture system can be used to benefit local communities, bolster the UK’s reputation as a pioneer in negative emission technologies, and provide a sustainable and commercially viable pathway to net-zero while also delivering national energy security.”
Ricardo’s project is one of several across the UK which will benefit from a share of over 54 million GBP to develop technologies that remove carbon emissions from the atmosphere. Announcing this investment, UK Government’s Energy and Climate Change Minister Greg Hands said: “This 54 million GBP government investment will help establish a greenhouse gas removal industry in the UK, which could be worth billions to our economy, bringing in private investment and supporting the creation of new green jobs.”
The technology works by taking sustainably sourced waste wood from domestic timber production and then processing it in three ways: producing biochar (a product similar to charcoal); generating heat and power; and capturing carbon dioxide from the exhaust. The technology, therefore, captures around 95% of the carbon content in the wood. It also produces commercially marketable carbon products: the biochar can be used by farmers to enrich soil and add to animal feed to reduce ruminant emissions. The industrial-grade carbon dioxide can either be used for making low-carbon concrete or in the food and drinks industry to replace carbon dioxide derived from industrial processes which rely on imported natural gas. A full-size system will remove 16,000 tonnes of carbon dioxide per year from the atmosphere.
Ricardo has been collaborating with Bluebox Energy since June 2020 to deliver innovative technologies that support the transition to a low carbon future. This project is a further boost to Ricardo’s credentials in tackling climate change and meeting national net zero targets. Ricardo is currently actively supporting clients in Europe in innovative carbon capture technologies and has advised the UK Government on the potential of bioenergy with carbon capture in the UK. Ricardo supports clients across a wide range of industries develop their industrial decarbonisation plans on the route to net zero.
Ends
About Ricardo
Ricardo plc is a world-class strategic, environmental, and engineering consulting company, listed on the London Stock Exchange. With over 100 years of engineering excellence and employing close to 3,000 employees in more than 20 countries, we provide exceptional levels of expertise in delivering leading-edge and innovative cross-sector sustainable products and solutions. Every day, we enable our customers to solve the most complex and dynamic challenges to help achieve a safe and sustainable world. Visit www.ricardo.com
Department for Business, Energy & Industrial Strategy
This funding has been made available from the government’s £1 billion Net Zero Innovation Portfolio , which looks to accelerate the commercialisation of low-carbon technologies and systems, through its Direct Air Capture and Greenhouse Gas Removal Innovation Competition. This competition will provide funding for developing technologies that enable the removal of greenhouse gases from the atmosphere in the UK.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220711005348/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom